University of Dundee, Biomedical Research Institute, Dundee DD1 9SY, Scotland, UK.
J Clin Endocrinol Metab. 2012 Jan;97(1):1-8. doi: 10.1210/jc.2011-1927.
Hypoglycemia remains a major clinical issue in the management of people with type 1 and type 2 diabetes. Research in basic science is only beginning to unravel the mechanisms that: 1) underpin the detection of hypoglycemia and initiation of a counterregulatory defense response; and 2) contribute to the development of defective counterregulation in both type 1 and type 2 diabetes, particularly after prior exposure to repeated hypoglycemia. In animal studies, the central nervous system has emerged as key to these processes. However, bench-based research needs to be translated through studies in human subjects as a first step to the future development of clinical intervention. This Update reviews studies published in the last 2 yr that examined the central nervous system effects of hypoglycemia in human subjects, largely through neuroimaging techniques, and compares these data with those obtained from animal studies and the implications for future therapies. Based on these studies, it is increasingly clear that our understanding of how the brain responds and adapts to recurrent hypoglycemia remains very limited. Current therapies have provided little evidence that they can prevent severe hypoglycemia or improve hypoglycemia awareness in type 1 diabetes. There remains an urgent need to increase our understanding of how and why defective counterregulation develops in type 1 diabetes in order for novel therapeutic interventions to be developed and tested.
低血糖仍然是 1 型和 2 型糖尿病患者管理中的一个主要临床问题。基础科学研究才刚刚开始揭示以下机制:1)支持低血糖的检测和代偿防御反应的启动;2)有助于 1 型和 2 型糖尿病中代偿调节的缺陷的发展,尤其是在先前经历反复低血糖之后。在动物研究中,中枢神经系统已成为这些过程的关键。然而,基础研究需要通过人体研究来转化,作为未来临床干预发展的第一步。本综述回顾了过去 2 年中发表的研究,这些研究通过神经影像学技术检查了低血糖对人体中枢神经系统的影响,并将这些数据与动物研究获得的数据进行了比较,以及对未来治疗的影响。基于这些研究,越来越明显的是,我们对大脑如何对反复发生的低血糖做出反应和适应的理解仍然非常有限。目前的治疗方法几乎没有证据表明它们可以预防严重低血糖或改善 1 型糖尿病患者的低血糖意识。迫切需要增加我们对 1 型糖尿病中代偿调节缺陷如何以及为何发展的理解,以便开发和测试新的治疗干预措施。